ArticleInternational ophthalmology2026
Retinal image-based cardiovascular risk prediction using AI-CRS: a multi-modal deep learning framework.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents AI-CRS, an AI-driven deep learning framework for cardiovascular risk assessment using retinal images. By combining convolutional neural networks (CNNs), attention mechanisms, and vasculature segmentation, AI-CRS overcomes the limitations of traditional methods, such as reliance on handcrafted features and single-modality data. The model integrates multi-modal information, fusing vasculature segmentation maps with raw image data to capture subtle vascular changes indicative of cardiovascular diseases. Experimental validation demonstrates that AI-CRS outperforms conventional diagnostic techniques in cardiovascular risk stratification, achieving superior sensitivity, specificity, and accuracy. The model excels in detecting early-stage disease and subtle vascular anomalies, and it shows strong generalizability across diverse datasets, patient demographics, and varying image qualities. Beyond cardiovascular risk, AI-CRS also shows promise in assessing systemic health conditions like hypertension and diabetes, demonstrating the broader utility of retinal imaging in health monitoring. The attention-driven architecture enhances model interpretability, providing clinicians with visual explanations of disease-associated vascular patterns, which is essential for clinical adoption. AI-CRS offers a non-invasive, scalable solution that can be integrated into routine clinical practice, supporting early diagnosis, personalized care, and population-wide screening. Its automated analysis reduces the need for manual feature extraction and subjective interpretation, streamlining workflows and improving efficiency. Ultimately, AI-CRS represents a significant step toward precision medicine by enabling timely interventions, reducing healthcare costs, and improving patient outcomes through non-invasive digital biomarkers.
Indexed as
Identifiers
41941015What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.